|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Both 3D pCASL and DWI could be useful tools for distinguishing low- from high-grade diffuse gliomas and have the potential to differentiate different IDH1 mutation statuses of astrocytoma.
|
29777252 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%).
|
30292978 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
By contrast MAP - 2 expression was significantly increased in diffuse astrocytomas with IDH mutation, while NOGO - A expression was not associated with any molecular marker.
|
29258767 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma.
|
29720725 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We showed that there was a subgroup, although small, of IDH-mutated astrocytomas harboring 19q-loss that present oligodendroglial morphology, and also were associated with significantly better prognosis compared to other 19q-intact astrocytomas.
|
29752851 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data.
|
29077933 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A discovery cohort of 211 IDH-mutant astrocytic gliomas with an extended observation was subjected to histological review, image analysis, and DNA methylation studies.
|
29687258 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas.
|
29027701 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant).
|
28042970 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
|
28124097 |
2017 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Meanwhile, the results from immunohistochemistry and DNA sequencing showed that, compared with primary astrocytoma, there was no change of IDH1 status in recurrent astrocytoma whatever tumour pathological grade raise or indolent.
|
28928859 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Non-canonical IDH mutations were identified in 13/52 (25.0%) grade II gliomas (astrocytomas: 8/31, 25.8%; oligodendrogliomas: 5/21, 23.8%) and in 5/40 (12.5%) grade III gliomas (astrocytomas: 3/25, 12.0%; oligodendrogliomas: 2/15, 13.3%).
|
28748342 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The IDH1 gene mutant and wildtype groups of WHO grade II, III, and IV astrocytoma showed differences in the rCBV ratio (P = 0.005, 0.045, and 0.005, respectively).
|
27367599 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among Group 5, IDH-wildtype astrocytomas, the TERT-WT group had significantly better overall survival than the TERT-MUT group (HR: 0.48, 95% CI 0.27-0.87), p = 0.02).
|
28255664 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP.
|
28327577 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
As expected, the methylation profiles of all four tumors were found to match most closely with IDH-mutant astrocytomas.
|
28421459 |
2017 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The chemokine signaling pathway could characterize subtypes of IDH wild-type astrocytomas.
|
29221210 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study.
|
28547590 |
2017 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in genes encoding enzymes involved in the tricarboxylic acid (TCA) cycle, such as the isocitrate dehydrogenases 1 and 2 (IDH1/2), are frequently encountered in astrocytomas and secondary glioblastomas, as well as in acute myeloid leukemias; however, the precise molecular mechanisms by which these mutations promote tumorigenesis remain to be fully characterized.
|
28711227 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest a potential usefulness of proliferation markers in the prognostic setting of astrocytomas independent of IDH1-mutation status, and survivin and TIIα are potential candidates in that regard.
|
28214203 |
2017 |
|
Astrocytoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our proteomic datasets are available for download and provide a comprehensive catalogue of alterations in protein abundance, phosphorylation, and histone modifications in oncogenic HRAS and IDH1 driven astrocytoma cells beyond the transcriptomic level.
|
27834733 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, loss of ATRX immunoexpression, shown for the first time in these tumors, along with immunopositivity for p53 and IDH1, indicates that these tumors are molecular astrocytomas, and their clinical behaviour is likely to recapitulate that of ATRX-mutant and IDH-mutant diffuse astrocytomas of the same grade.
|
27469217 |
2016 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups.
|
26493382 |
2016 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We therefore evaluated the prognostic impact of extensive, mainly intraoperative (i)MRI-guided surgery in low-grade astrocytomas stratified for IDH1 mutation status.
|
27344556 |
2016 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
DNA methylation analyses revealed 5'-CpG site hypermethylation of miR-346 in more than two-thirds of primary glioblastomas, while aberrant 5'-CpG site methylation of miR-146b-5p was frequent in IDH1-mutant astrocytomas and secondary glioblastomas.
|
26223576 |
2016 |